Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

10 Years of Athena Swan

Athena Swan recognises a department’s commitment to gender equality, to understanding their own culture and context, to engaging with their communities and to committing to detailed and ambitious action plans in response to data and consultation.

NDORMS submitted an application for the Athena Swan Bronze Award in November 2013, and achieved this in 2014.

In 2015 NDORMS submitted and achieved the application for the Athena Swan Silver Award, which was renewed in 2018.

There are many initiatives within NDORMS that have helped us to achieve the Silver Award, and lots of people that have helped us to get there.


NDORMS Mediation Service

In 2022 we launched an internal Mediation Service. Led by Maria Granell Moreno and Isuara Thomas, the service helps to informally manage workplace conflicts and learn from them. The Mediation Service is open to staff and students who find themselves in conflict with another member of staff or student, and provides a confidential space and a chance to voice feelings and hear things from the other person’s perspective. 

Mediation helps to improve our working environment and research culture by empowering individuals and teams to manage their conflicts efficiently, informally and constructively.

NDORMS will share the progress of the Mediation Service with the wider University and will potentially help to launch this in other departments.

Find out more about the Mediation Service.  



The Taught MSc in Musculoskeletal Sciences is a part-time two-year course integrating orthopaedics and rheumatology. The vision is to train the future leaders in the field of musculoskeletal sciences. 

In 2017 Professor Steph Dakin was appointed as the Director of Graduate Studies for the course. Since then, we have increased our efforts to balance the gender ratio and attract more female candidates to the course. 

Taught MSc infographic

Working with the Communications Team, we have used social media to reach potential female students. We also ensure that women are represented on the course. The Course Director is female, as are several members of the Organising Committee, and we strive to have 50% on-course teaching materials contributed by women. 

Find out more about the Taught MSc.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.